

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-4 (Cancelled).

Claim 5 (Currently Amended) A method for treating Alzheimers Disease (AD) in a patient in need of such treatment, the method comprising

contacting blood or plasma flow of a patient suffering from AD or a patient with a risk for AD with an apheresis device, the apheresis device comprising a solid carrier, said solid carrier having anti-amyloid- β precursor protein (APP) [[APP]] antibodies attached to a surface of the solid carrier, and wherein contacting with the apheresis device is for a time sufficient to reduce APP polypeptides and treat AD in the patient.

Claim 6. (Previously Presented) The method according to claim 5, wherein the anti-APP-antibodies are anti-Abeta40 antibodies or anti-Abeta42 antibodies.

Claim 7 (Previously Presented) The method according to claim 5, wherein the anti-APP-antibodies are anti-Abeta40 antibodies.

Claim 8 (Previously Presented) The method according to claim 5, wherein the anti-APP-antibodies are anti-Abeta42 antibodies.

Claim 9. (Previously Presented) The method according to claim 5, wherein the carrier is a sterile and pyrogen-free column.

Claim 10 (Previously Presented) The method according to claim 5, wherein the method comprises contacting blood or plasma flow of a patient suffering from AD.

Claim 11 (Currently Amended) The method according to claim 5, wherein the method comprises contacting blood or plasma flow of a patient with a risk for AD.